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Endo B (melanotic) and W (amelanotic) human malig-
nant melanomas originated from the same tumor, both 
known to be heterogeneous in drug sensitivity to 
ACNU ([ 1- ( 4-amino-2-methyl-5-pyrimidiny 1)-methyl-
3 - (2-choletbyl)-3-nitrosourea hydrochloride]), were 
treated experimentally with a combination therapy of 
ACNU and hyperthermia in mice. Whereas Endo W 
melanoma bas no sensitivity, En do B melanoma is 
sensitive to ACNU alone. However, in both types of 
melanomas, a marked synergistic effect of the combi-
nation therapy was noted. Histologically, marked de-
generation of both tumor cells was detected. These 
results strongly suggest that thermocbemotherapy 
may overcome the tumor heterogeneity in drug sensi-
tivity. 
It is accepted that the tumor is not composed of a single cell 
population but is heterogeneous in drug sensitivity [1- 3] and 
metastatic ability [4- 6]. Especially, heterogeneity in drug sen-
sitivity is a critical issue in the chemotherapy of tumor. The 
so-called drug-resistant ce lls which exist resultantly following 
the use of various sorts of chemotherapy are a serious obstacle 
yet to be surmounted, and these resistant cells are now the 
most important problem of chemotherapy. 
Endo B and W human melanoma strains [7-8] established 
at Chiba Cancer Center in 1978 are two types of melanoma 
strains which have been obtained from the same tumor, sepa-
rated, and subcultured. A subsequent study [8] has demonstra-
ted that Endo W melanoma has no sensitivity to a variety of 
drugs. 
Since t he 1970s, hyperthermia has been shown to act syner-
gistically with some antitumor agents in vitro [9- 10], in animals 
[11- 13] and in humans (14- 17], in various kinds of tumors. 
Using these two types of melanomas which are heterogeneous 
in drug sensit ivity, we investigated the possibility of overcoming 
heterogeneity in drug sensitivity by means of thermochemo-
therapy. 
MATERIALS AND METHODS 
Animals 
Male BALB/c-nu mice, 5- 7 weeks old, purchased from the Nippon 
Clea Co., were used in this experiment. The an imals were bred under 
SPF facil ities using steri lized a luminium gauge and fi lter cap, and were 
given Co-irradiated feed and water steri lized by high-pressure steam. 
Tumors 
Endo 8 and W melanomas were suppl ied by Chiba Cancer Center. 
These two types of melanomas were obtained ftom the same tumor. 
EndoW melanoma (amelanotic melanoma) spontaneously arose from 
the original melanotic mell:moma during the transplantation in nude 
mice. Subcutaneous Endo B melanoma of the nude mouse was a well -
demarcated, blue-black, and elastic hard tumor. Histopathologically, 
tumor cells contained plentifu l melanin, and the nuclei were large and 
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oval shaped similar to original primary tumor cells. Electron micro-
scopic findings depict numerous melanosomes (stages II- IV), most of 
which are in the process of melanization in the cytoplasm of tumor 
cells. In drug sensitivity, Endo B melanoma is sensitive to ACNU (Fig 
1a). On the other hand, subcutaneous Endo W melanoma was a well-
demarcated, yellowish-white, hard tumor. Histopathologically, tumor 
cells resemble those of Endo B melanoma, but without melanin. Elec-
tron microscopic findings revealed numerous unmelanized melano-
somes (stages I and II) in the cytoplasm. Endo W melanoma has no 
sensitivity to ACNU (Fig 1b ). 
Drug 
ACNU was supplied by the Sankyo Co. The drug was kept in a dark 
environment and dissolved in distilled water before injection. In a 
concentration of 10 mg/ kg it was administered i.p. q4d, for a total of 3 
times. 
Topical Heating 
A T-80 thermostat (Tokyo Rika Co.) was used for topical heating. A 
digital thermometer (Baley Co.) was used for measurement of temper· 
ature. The temperature of the water bath was stabilized at 43.5"C ± 
0.1. This temperature has been generally used as the most effective for 
experimental and clinical use [18-20]. Immediately after ACNU ad-
ministration, the animals were anesthetized with i.p. administration of 
Ketamin hydrochloride (Ketamin) 3 rug/ kg and then soaked for 30 min 
in a water bath. In view of possible undesirable effects of Ketamin on 
the animals, the same dose was administered i.p. to all the animals. 
Evaluation of Tumors 
Tumor growth curve: Tumors in each animal group were measured 
by slide callipers at least twice a week to calculate the tumor volume 
using the following formu la: 
where a = long diameter and b = short diameter. Using the mean 
volume of the tumors in each group, a tumor growth curve of each 
group was obta ined. 
Relative maximal suppression rate of tumor (T/C): The maximal 
value ofT /C was obtained by the foll owing formul a: 
Tn / Cn X 100 
To Co 
where Tn = tumor volume of day n in treated group, To = tumor 
volume of day 0 in treated group, Cn = tumor volume of day n in 
control group, and Co = tumor volume of day 0 in control group. 
Histopathology: The tumors from each group of Endo 8 and Endo 
W melanoma were isolated at 14 days after the final treatment and 
immediately fixed with 10% formalin . Hematoxylin and eosin-stained 
tumors were submitted for light microscopic examination. 
RESULTS 
Endo B Melanoma 
This experiment was done using animal groups of 5 mice 
each. T he tumors from each group were sampled randomly. 
Tumor growth curve (Fig 2): Tumors from the control group 
and heat group grew up nearly in parallel. In the ACNU group, 
the growth rate declined after the first treatment. However, 
this group again showed an upward tumor growth, with no 
appreciable difference from the control group after day 12. The 
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FIG 1. Tumor growth curves at a dose of 20 mg/kg ACNU given fo r 
6 doses. a, Endo B melanoma. T he ACNU group showed marked 
reduction after the fi rst treatment. b, Endo W melanoma. T he ACNU 
group and control group showed a similar growth rate. A rrows = 
t reatment, g refers to the weight of animals. 
ACNU + heat group showed a marked ant it umor effect. No 
growth of tumors was observed fo r a period of about 34 days 
after t he second t reatment . In t he t umor growth delay, t he 
ACNU + heat group revealed prolongations of 58 days and 44 
days as compared wit h t he cont rol group and t he ACNU group 
(Table I) . 
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FIG 2. Endo B melanoma. Tumor growth curves. Tumor growth Of 
the ACNU + heat group was inhibited for about a month after t he fi rst 
treatment. Bars = SE, arrows = treatment, g refers to the weight of 
animals. 
TABL E I. T umor growth delay and relative maximal suppression rate 
of tumor (T/C) 
Tumor growth delay 
(days) 
Endo B melanoma 
Control 0 
ACNU 14 
ACNU +heat 58 
Heat 5 
Endo W melanoma 
Cont rol 0 
ACNU - 4 
ACNU + heat 35 
Heat - 6 
" Significant ly different from controls, p < 0.01. 
b Significant ly different from controls, p < 0.05. 
T /C 
(%) 
52 
16.4" 
60.2 
69.8 
17.6b 
58.6 
Relative maximal suppression rate of tumor (T /C) : T /C in 
each group is shown in T able I. No t herapeutic effect wa.s 
observed in t he heat group and ACN U group. In t he ACNU -+-
heat group, an excellent t herapeut ic T /C of 16.4% was obtaine<:J.. 
Histopathology: A more advanced central necrosis compa red 
wit h t hose of t he cont rol and ACNU a lone groups was observe<:J.. 
In t umor cells, vacuolized and pyknotic nuclei were remarkable 
wit h increased amounts of melanin. 
Endo W M elanoma 
Tumor growth curve: Fig 3 shows t he t umor growth curve ()f 
each group. Both t he heat group and t he ACN U group reveale d 
a simila r growth rate compared wit h t he cont rol group. On t h.e 
other hand, in the ACNU + heat group the tumor growth Wf\s 
markedly suppressed after the secound t reatmen t . In t he t um()r 
growth delay (Table I) , t he ACNU + heat group showed pr()_ 
longations of 35 days a nd 39 days as compared wit h t he con tr () l 
group and t he ACNU group . 
Relative maximal suppression rate of tumor (T /C): No t herq-
peut ic a nt it umor effect was recognized in t he heat group aQ.d 
ACN U group. The ACNU + heat group showed a marke d 
ant itumor effect wit h a T /C of 17.6% (Table I) . 
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FIG 3. Endo W melanoma. Tumor growth curves. The ACNU + 
heat group showed a marked antitumor effect. Bars = SE arrows = 
treatment, g refers to the weight of a nima ls. ' 
Histopathology: In t he ACNU + heat group , widespread de-
generati~e alterations of tumor cells were recognized. High-
power v1ew of tumor cells showed a marked vacuolization of 
the nuclei. 
DISCUSSION 
Endo melanoma stra ins are human malignant melanomas 
established at Chiba Cancer Center in 1978 [7,8] which were 
obtained from a metastasized tumor lesion in the pleural wall 
in a 45-year-old man. During subcul tures of the strain im-
planted s.c. in nude mice, it was observed t hat an amelanotic 
lesion appeared in a part of the original melanotic tumor then 
both were separated and subjected to respective subcultures. 
As a result, the original melanotic melanoma was termed Endo 
B melanoma and t he amelanotic melanoma, Endo W mela-
noma. Subsequent studies [8) have demonstrated that t hese 
two types of melanoma stra ins are heterogeneous in metastatic 
ability and drug sensitivity. When Endo B melanoma was 
implanted s.c. in nude mice, metastasis to local lymph nodes 
was noted in approximately 57% of the animals within 5 weeks 
after transplantation; further, hematogenous metastasis to the 
liver and lung was also noted. On the other hand, in Endo W 
melanoma, metastasis to local lymph nodes was recognized 
only after a long-term observation of more t han 3 months· no 
hematogenous metastasis to the liver and lung was confir~ed. 
Furthermore, h~terogeneity of both types in drug sensit ivity 
was found promment, E ndo W melanoma exhibi ts no sensitiv-
ity to a number of drugs including DTIC [5-(3.3-dimethyl-1-
triazeno) imidazole-4-carboxamide], vincristine, and bleomycin 
which are sensitive to Endo B melanoma [8). On the contrary 
Endo W melanoma shows sensit ivity to melphalan and Adria~ 
mycin, t.o neith~r of :-vhich En.do B melanoma has sensitivity 
[8). Tokita provided further evidence demonstrating t hat Endo 
W melanoma had no sensitivity to a nitrosourea, ACNU. These 
findings indicate that E ndo B melanoma is higher in malig-
nancy clinically in respect to metastasicity, whereas Endo W 
melanoma is higher in respect to drug sensit ivity. 
These two types of melanoma strains derived from the same 
tumor are collaborative evidence demonstrating the ex istence 
of heterogeneity in metastasicity and drug sensit ivity in a single 
cell population as asserted by Fidler and Kripke [5) and Shabel 
(1) . 
The e~istence of t his heterogenity in drug sensitivity is the 
~ost senousproblem for cancer chemotherapy. Namely, follow-
mg the applicatiOn _o~ various kinds of chemotherapy, if such 
cells as are nonsensitive to the given drug exist in a part of the 
tumor, the therapy employed not only would be useless but 
als? would result in many side effects. These so-called clrug-
resJstant cells are a.n i:nportant theme for cancer chemot herapy 
to overcome, and 1t IS hoped that studies of this theme will 
~ventua lly solve the problem of heterogeneity in drug sensitiv-
Ity. 
I~ the present stu?y, Endo W melanoma, ACNU-resistant 
stram, was t reated w1t~ ACNU combined with thermotherapy, 
and the same suppressive effect as in Endo B melanoma which 
is originally sensitive to ACNU was obtained; histologically, a 
remarkable nuclear degeneration was noted. These findings 
seemed very interesting and led us to consider the role that 
heating might play in the incorporation of the drug in drug-
resistant cells. 
There have been experimental studies reporting [9-14) on 
an enhancement of t he activit ies of antitumor drugs in the 
combination use of thermotherapy. In clinical application, the 
hyperthermia in combination with chemotherapeutic agents or 
radiation has a lso been observed to act effectively using 
microwave [1 9,20], ultrasound (21,22], and radiofrequencies 
[15,18,23) at a temperature in the range of 40-44 ·c In our 
previous study (24], we also confi rmed the reinforced activ-
ities of ACNU combined with thermotherapy in t he t reat-
ment of malignant melanoma. However, little is known about 
t he mechanism of t he action of heating, and t here have been 
a va riety of speculations about it [25- 27]. The most inter-
esting one [25 ) is related to t he effect upon t he ce ll mem-
brane. This is based on the assertion that most antitumor 
drugs flow in to t he ce ll t hrough its lipophilic membrane. In 
fact, Hall [25) reported t hat the intacellular concentration 
was higher at 43 "C t han at 37"C in a study using Adriamycin. 
While the mechanism of formation of drug-resistant cells 
seems to be different among different drugs, none of the drugs 
can exert their effects without passing through the cell mem-
brane. In an attempt to explain the multidrug-resistant cells, 
the active transport of cell membrane, i.e., "active efflux," has 
recently been proposed. This proposal implies t hat the resistant 
cells may actively draw certain drugs from the cells to lower 
the intracellular drug concentration, resulting in diminution of 
the drug effects [28). In fact, there are efflux-inhibiting agents 
in support of this proposal. Tsuruo et al [29) reported interest-
ing results of their study using calcium antagonists, efflux-
inhibiting agents, for overcoming the cellular resistance to 
various drugs. The proposed "active efflux" of the cell mem-
brane raises the possibility that heating may act on the metab-
olism of the membrane of the drug-resistant cells, with involve-
ment not only in uptake but also in efflux of the drugs. 
The findings obta ined in the present study, although on only 
one drug, seem to strongly suggest that heating may play an 
important role in overcoming the cellular resistance to chemo-
therapeutic agents. 
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